BOTHELL, Wash., Dec. 8 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. , a leading developer and marketer of proprietary cGMP hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that it has been granted a European patent for an application that includes claims related to protecting cells from injury and death caused by cold temperatures used in biopreservation. The patent titled, “Inclusion of Apoptotic Regulators in Solutions for Cell Storage at Low Temperature,” was previously granted US patent protection.
Mike Rice, BioLife’s chairman and CEO, noted that the new patent expands the protections of the Company’s key intellectual property related to regulating the biologic process of apoptosis (programmed cell death) in response to the accumulated stress due to exposure to hypothermic and freezing temperatures. The new patent is a direct result of BioLife’s ongoing effort to increase the value of its intellectual property portfolio and enable additional product and licensing revenue streams for BioLife, he added.
“We’ve repeatedly shown via numerous internal and customer validations that our products better protect cells and tissues from the harmful necrotic and apoptotic effects of hypothermic storage, freezing, and thawing, and as a result, can extend the shelf life and improve the post preservation recovery, viability, and functional yield of both biologic source material as well as isolated cells,” Rice said, adding that the Company has submitted several additional patent applications during 2008.
About BioLife Solutions, Inc.:
BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company’s proprietary HypoThermosol(R) and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife’s cGMP products are serum-free and protein-free, fully defined, and formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife’s enabling technology provides research and clinical organizations significant improvement in post-preservation cell and tissue viability and function. For more information please visit http://www.biolifesolutions.com.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions’ actual results to differ materially are discussed in the Company’s recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
CONTACT: Media, Len Hall, len@allencaron.com, or Investor Relations, Matt
Clawson, matt@allencaron.com, both of Allen & Caron Inc, +1-949-474-4300,
for BioLife Solutions, Inc.
Web site: http://www.biolifesolutions.com/
